Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
77 hedge funds and large institutions have $586M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 4 closing their positions.
900% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 4
351% more capital invested
Capital invested by funds: $130M → $586M (+$456M)
244% more call options, than puts
Call options by funds: $592K | Put options by funds: $172K
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
88% more funds holding
Funds holding: 41 → 77 (+36)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.52M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$4.83M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.62M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$3.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.5M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.31M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$633K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$299K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$171K |
FUSN Hedge Fund Activity: Q4 2023 in Review
77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2023, worth a combined $586M — up 351% from $130M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new FUSN positions and 4 closed out — a net gain of 36 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Deerfield Management, adding an estimated $17.4M. The largest seller was Artal Group, cutting an estimated $3.5M.
- 77 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2023, up from 41 in Q3 2023.
- Funds reported $586M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2023, up 351% quarter-over-quarter.
- 40 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2023 and 4 closed out, a net change of +36 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2023 was Deerfield Management, an estimated $17.4M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2023 was Artal Group, an estimated $3.5M sold.
Based on aggregated 13F filings for Q4 2023.